Alkem Laboratories is currently trading at Rs. 6105.00, up by 31.15 points or 0.51% from its previous closing of Rs. 6073.85 on the BSE.
The scrip opened at Rs. 6030.55 and has touched a high and low of Rs. 6168.45 and Rs. 6030.55 respectively. So far 2769 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6203.10 on 30-Aug-2024 and a 52 week low of Rs. 3440.05 on 05-Oct-2023.
Last one week high and low of the scrip stood at Rs. 6203.10 and Rs. 5853.20 respectively. The current market cap of the company is Rs. 73137.31 crore.
The promoters holding in the company stood at 56.38%, while Institutions and Non-Institutions held 27.26% and 16.36% respectively.
Alkem Laboratories has signed a patent licensing agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan in India. The medication (in strengths of 10 and 20 mg) is indicated in the treatment of reflux esophagitis (RE) and other indications such as gastric ulcers and duodenal ulcers, among others.
The company has a formidable presence in the gastrointestinal segment and this non-exclusive patent licence with Takeda will help it offers a product with novel mechanism of action for a large number of patients in India who are suffering from gastro-related ailments.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
